Clinical Edge Journal Scan

Key clinical point: Patients with rheumatoid arthritis (RA) with high baseline fibromyalgianess were more likely to use glucocorticoid persistently at 3 months follow-up, regardless of inflammatory activity.

Major finding: After adjusting for potential confounders including noninflammatory and inflammatory factors, patients with high or very high vs low fibromyalgianess were significantly more likely to be taking prednisone (adjusted odds ratio, 4.99; 95% confidence interval, 1.20-20.73) at 3-month follow-up.

Study details: Findings are from an analysis of 97 patients with active RA from the prospective Central Pain in RA (CPIRA) cohort, who were on oral prednisone for 3 months after starting a new disease-modifying antirheumatic drug.

Disclosures: The CPIRA study was funded by the National Institute of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. YC Lee, MB Bolster, and DJ Clauw reported receiving consulting fees, speaking fees, honoraria, and/or stock ownership from various sources. All the other authors declared no conflict of interests.

Source: Wallace BI et al. Rheumatology (Oxford). 2021 Jul 22. doi: 10.1093/rheumatology/keab583.

Key clinical point: Patients with rheumatoid arthritis (RA) with high baseline fibromyalgianess were more likely to use glucocorticoid persistently at 3 months follow-up, regardless of inflammatory activity.

Major finding: After adjusting for potential confounders including noninflammatory and inflammatory factors, patients with high or very high vs low fibromyalgianess were significantly more likely to be taking prednisone (adjusted odds ratio, 4.99; 95% confidence interval, 1.20-20.73) at 3-month follow-up.

Study details: Findings are from an analysis of 97 patients with active RA from the prospective Central Pain in RA (CPIRA) cohort, who were on oral prednisone for 3 months after starting a new disease-modifying antirheumatic drug.

Disclosures: The CPIRA study was funded by the National Institute of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. YC Lee, MB Bolster, and DJ Clauw reported receiving consulting fees, speaking fees, honoraria, and/or stock ownership from various sources. All the other authors declared no conflict of interests.

Source: Wallace BI et al. Rheumatology (Oxford). 2021 Jul 22. doi: 10.1093/rheumatology/keab583.

Key clinical point: Patients with rheumatoid arthritis (RA) with high baseline fibromyalgianess were more likely to use glucocorticoid persistently at 3 months follow-up, regardless of inflammatory activity.

Major finding: After adjusting for potential confounders including noninflammatory and inflammatory factors, patients with high or very high vs low fibromyalgianess were significantly more likely to be taking prednisone (adjusted odds ratio, 4.99; 95% confidence interval, 1.20-20.73) at 3-month follow-up.

Study details: Findings are from an analysis of 97 patients with active RA from the prospective Central Pain in RA (CPIRA) cohort, who were on oral prednisone for 3 months after starting a new disease-modifying antirheumatic drug.

Disclosures: The CPIRA study was funded by the National Institute of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. YC Lee, MB Bolster, and DJ Clauw reported receiving consulting fees, speaking fees, honoraria, and/or stock ownership from various sources. All the other authors declared no conflict of interests.

Source: Wallace BI et al. Rheumatology (Oxford). 2021 Jul 22. doi: 10.1093/rheumatology/keab583.

Key clinical point: Long-term use of tumor necrosis factor inhibitors (TNFis) for rheumatoid arthritis (RA) in clinical practice was not associated with an increased incidence of overall cancer. However, a higher risk of developing urinary tract cancer was observed for TNFi, rituximab, and abatacept.

Major finding: Compared with biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD)-naive patients, the relative risk for overall cancer was not higher among those treated with TNFis for 10 or more years (adjusted hazard ratio [aHR], 1.0; 95% confidence interval [CI], 0.8-1.2). However, the risk for urinary tract cancer was significantly higher with TNFi (aHR, 1.5; 95% CI, 1.1-1.9), rituximab (aHR, 2.1; 95% CI, 1.3-3.7), and abatacept (aHR, 2.3; 95% CI, 1.3-3.9).

Study details: This was an observational cohort study that included patients with RA (n=69,308) who received TNFis or other b/tsDMARDs, b/tsDMARDs-naïve patients with RA (n=56,233), and matched general population referents (n=109,532).

Disclosures: This study was funded by the Karolinska Institute Region Stockholm. J Askling declared research agreements with various sources. The other authors declared no conflict of interests.

Source: Huss V et al. Rheumatology (Oxford). 2021 Jul 29. doi: 10.1093/rheumatology/keab570.

Key clinical point: Long-term use of tumor necrosis factor inhibitors (TNFis) for rheumatoid arthritis (RA) in clinical practice was not associated with an increased incidence of overall cancer. However, a higher risk of developing urinary tract cancer was observed for TNFi, rituximab, and abatacept.

Major finding: Compared with biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD)-naive patients, the relative risk for overall cancer was not higher among those treated with TNFis for 10 or more years (adjusted hazard ratio [aHR], 1.0; 95% confidence interval [CI], 0.8-1.2). However, the risk for urinary tract cancer was significantly higher with TNFi (aHR, 1.5; 95% CI, 1.1-1.9), rituximab (aHR, 2.1; 95% CI, 1.3-3.7), and abatacept (aHR, 2.3; 95% CI, 1.3-3.9).

Study details: This was an observational cohort study that included patients with RA (n=69,308) who received TNFis or other b/tsDMARDs, b/tsDMARDs-naïve patients with RA (n=56,233), and matched general population referents (n=109,532).

Disclosures: This study was funded by the Karolinska Institute Region Stockholm. J Askling declared research agreements with various sources. The other authors declared no conflict of interests.

Source: Huss V et al. Rheumatology (Oxford). 2021 Jul 29. doi: 10.1093/rheumatology/keab570.

Key clinical point: Long-term use of tumor necrosis factor inhibitors (TNFis) for rheumatoid arthritis (RA) in clinical practice was not associated with an increased incidence of overall cancer. However, a higher risk of developing urinary tract cancer was observed for TNFi, rituximab, and abatacept.

Major finding: Compared with biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD)-naive patients, the relative risk for overall cancer was not higher among those treated with TNFis for 10 or more years (adjusted hazard ratio [aHR], 1.0; 95% confidence interval [CI], 0.8-1.2). However, the risk for urinary tract cancer was significantly higher with TNFi (aHR, 1.5; 95% CI, 1.1-1.9), rituximab (aHR, 2.1; 95% CI, 1.3-3.7), and abatacept (aHR, 2.3; 95% CI, 1.3-3.9).

Study details: This was an observational cohort study that included patients with RA (n=69,308) who received TNFis or other b/tsDMARDs, b/tsDMARDs-naïve patients with RA (n=56,233), and matched general population referents (n=109,532).

Disclosures: This study was funded by the Karolinska Institute Region Stockholm. J Askling declared research agreements with various sources. The other authors declared no conflict of interests.

Source: Huss V et al. Rheumatology (Oxford). 2021 Jul 29. doi: 10.1093/rheumatology/keab570.

Key clinical point: In patients with rheumatoid arthritis (RA), treatment with targeted synthetic and biologic disease-modifying antirheumatic drugs (tsDMARDs/bDMARDs) vs conventional synthetic DMARDs (csDMARDs) was associated with a significantly higher risk for herpes zoster (HZ).

Major finding: Compared with csDMARDs, Janus kinase inhibitors (adjusted hazard ratio [aHR], 3.66; P less than .0001), monoclonal anti-tumor necrosis factor antibodies (aHR, 1.63; P = .0042), and B-cell targeted treatment (aHR, 1.57; P = .0355) were associated with a significantly higher risk for HZ.

Study details: The data come from an analysis of 13,991 patients with RA from the German RABBIT register, which included patients who initiated tsDMARD/bDMARD or csDMARD treatment after at least 1 prior DMARD.

Disclosures: RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB. A Strangfeld, A Zink, GR Burmester, and J Braun declared receiving speaker fees, honoraria, consulting, and/or grants from various sources.

Source: Redeker I et al. Ann Rheum Dis. 2021 Jul 28. doi: 10.1136/annrheumdis-2021-220651.

Key clinical point: In patients with rheumatoid arthritis (RA), treatment with targeted synthetic and biologic disease-modifying antirheumatic drugs (tsDMARDs/bDMARDs) vs conventional synthetic DMARDs (csDMARDs) was associated with a significantly higher risk for herpes zoster (HZ).

Major finding: Compared with csDMARDs, Janus kinase inhibitors (adjusted hazard ratio [aHR], 3.66; P less than .0001), monoclonal anti-tumor necrosis factor antibodies (aHR, 1.63; P = .0042), and B-cell targeted treatment (aHR, 1.57; P = .0355) were associated with a significantly higher risk for HZ.

Study details: The data come from an analysis of 13,991 patients with RA from the German RABBIT register, which included patients who initiated tsDMARD/bDMARD or csDMARD treatment after at least 1 prior DMARD.

Disclosures: RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB. A Strangfeld, A Zink, GR Burmester, and J Braun declared receiving speaker fees, honoraria, consulting, and/or grants from various sources.

Source: Redeker I et al. Ann Rheum Dis. 2021 Jul 28. doi: 10.1136/annrheumdis-2021-220651.

Key clinical point: In patients with rheumatoid arthritis (RA), treatment with targeted synthetic and biologic disease-modifying antirheumatic drugs (tsDMARDs/bDMARDs) vs conventional synthetic DMARDs (csDMARDs) was associated with a significantly higher risk for herpes zoster (HZ).

Major finding: Compared with csDMARDs, Janus kinase inhibitors (adjusted hazard ratio [aHR], 3.66; P less than .0001), monoclonal anti-tumor necrosis factor antibodies (aHR, 1.63; P = .0042), and B-cell targeted treatment (aHR, 1.57; P = .0355) were associated with a significantly higher risk for HZ.

Study details: The data come from an analysis of 13,991 patients with RA from the German RABBIT register, which included patients who initiated tsDMARD/bDMARD or csDMARD treatment after at least 1 prior DMARD.

Disclosures: RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Hexal, Lilly, MSD, Viatris, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB. A Strangfeld, A Zink, GR Burmester, and J Braun declared receiving speaker fees, honoraria, consulting, and/or grants from various sources.

Source: Redeker I et al. Ann Rheum Dis. 2021 Jul 28. doi: 10.1136/annrheumdis-2021-220651.

Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.